Request Demo

Last update 27 Apr 2026

Nimodipine

Last update 27 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate, isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate, Nimodi pian

+ [33]

Target

Cav2.1

Action

inhibitors

Mechanism

Cav2.1 inhibitors(calcium voltage-gated channel subunit alpha1 A inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesOther Diseases+ [1]

Active Indication

Intracranial AneurysmNerve injurySubarachnoid Hemorrhage+ [1]

Inactive Indication

AIDS Dementia ComplexAneurysm, Intracranial Berry, 1

Originator Organization

Bayer AG

Active Organization

Bayer Vital GmbH

Beijing Deli Furui Pharmaceutical Technology Co. Ltd.

Azurity Pharmaceuticals, Inc.

+ [3]

Inactive Organization

Bayer Pharmaceuticals Corp.

Grace Therapeutics, Inc.Miles Laboratories, Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (28 Dec 1988),

Intracranial AneurysmSubarachnoid Hemorrhage

RegulationOrphan Drug (United States), Orphan Drug (European Union), Fast Track (United States)

Structure/Sequence

Molecular FormulaC21H26N2O7

InChIKeyUIAGMCDKSXEBJQ-UHFFFAOYSA-N

CAS Registry66085-59-4

Clinical Trials associated with Nimodipine

NCT06900998

/ Not yet recruitingPhase 2IIT

A Pilot Study on the Effects of Nimodipine on Alcohol Drinking Among Adults Who Are Heavy Alcohol Drinkers

This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipine 90 mg/dose every six hours during an 18-hour period prior to the ADP to allow for the limited central nervous system bioavailability of this drug. Electroencephalogram (EEG) data will be collected before the first dose and after the last dose of nimodipine. Adverse events will be closely monitored during this period. During the ADP session participants will receive a priming dose of alcohol followed by a one-hour monitoring period. This will be followed by three one-hour self-administration periods; during each hour, participants will be able to choose between drinking up to four drinks or receive the monetary equivalents of these drinks (total of 12 drinks over three hours).

Start Date01 Sep 2026

Sponsor / Collaborator

Yale University

[+1]

ISRCTN84570528

/ Not yet recruitingPhase 2IIT

A proof-of-concept, open, single-site exploratory study investigating the safety and tolerability of oral nimodipine and the effect it has on visual function in acute optic neuritis

Start Date09 Feb 2026

Sponsor / Collaborator

University College London

NCT07144956

/ Not yet recruitingPhase 3IIT

Is Adding Cilostazol to Nimodipine Improving Neurological Outcome of Patients With Aneurysmal Subarachnoid Hemorrhage? A Randomized, Double Blind, Placebo-controlled Trial

The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.

Start Date15 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Saint-Anne

100 Clinical Results associated with Nimodipine

100 Translational Medicine associated with Nimodipine

100 Patents (Medical) associated with Nimodipine

5,334

Literatures (Medical) associated with Nimodipine

01 May 2026·JOURNAL OF CLINICAL NEUROSCIENCE

Nimodipine dosing and pharmacokinetic variability in subarachnoid hemorrhage patients

Article

Author: Livermore, Amelia ; Stuart, Janine ; Smith, Melissa-Lassig ; Fourie, Cheryl ; Roberts, Jason A ; Wallis, Steven C ; Bellapart, Judith ; Wu, Xiaolin ; Hernández-Mitre, María Patricia

BACKGROUND:

Nimodipine remains the only prophylaxis for delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (SAH). The multifactorial etiology and variable presentation of DCI preclude dosing decisions based on clinical status. Despite this, nimodipine is routinely administered at a fixed dose, irrespective of patient-specific factors such as body weight, organ function, or penetration into target site. Characterizing nimodipine pharmacokinetics may enable individualized dosing approaches to improve treatment efficacy. Our objective is to describe the plasma and cerebrospinal fluid (CSF) pharmacokinetics of enteral nimodipine in SAH patients.

METHODS:

SAH patients ≥ 18 years with a clinical indication for nimodipine underwent serial plasma and CSF sampling. Nimodipine concentrations were quantified using ultra-high performance liquid chromatography coupled with tandem mass spectrometry. Pharmacokinetics were analysed using noncompartmental methods and nonlinear mixed-effects modelling. The effects of route of administration (oral versus nasogastric tube) and feeding state (fed versus fasted) were assessed.

RESULTS:

Thirty patients were included (70% females; mean weight 78.6 ± 20 kg; mean age 57 ± 12 years; 30% ≥65 years). A two-compartment population pharmacokinetic model with first-order absorption and linear elimination best fit the data, with age identified as a significant covariate on clearance. The median CSF-to-plasma exposure ratio was 0.35%, indicating minimal CSF penetration with high interindividual variability. Food markedly reduced nimodipine bioavailability, with lower plasma exposure observed for both oral and nasogastric administration in the fed versus fasted state.

CONCLUSION:

Nasogastric administration and non-fasting states may reduce nimodipine's bioavailability. CSF penetration was minimal and highly variable. The population pharmacokinetic model identified age as a significant determinant of clearance. Optimizing the administration of nimodipine may be required. Further large-scale studies focusing on the definition of nimodipinés optimal dosing are warranted.

01 Mar 2026·STROKE

Vasospasm During Endovascular Treatment of Ischemic Stroke: Associated Factors, Impact on Outcomes, and the Effect of Intraarterial Nimodipine

Article

Author: Berndt, Maria Teresa ; Boeckh-Behrens, Tobias ; Nolte, Christian H. ; Ernemann, Ulrike ; Alegiani, Anna ; Nolte, Christian ; Flottmann, Fabian ; Riegler, Christoph ; Zimmermann, Hanna ; Gröschel, Klaus ; Röther, Joachim ; Thomalla, Götz ; Bormann, Albrecht ; Dorn, Franziska ; Keil, Fee ; Wischmann, Johannes ; Poli, Sven ; Berrouschot, Jörg ; Wunderlich, Silke ; Abruscato, Mario ; Rattenberger, Alexander ; Petzold, Gabor ; Uphaus, Timo ; Schell, Maximilian ; Schäfer, Jan Hendrik ; Eckert, Bernd ; Fiehler, Jens ; Tiedt, Steffen ; Reich, Arno ; Thonke, Sven ; Kellert, Lars ; Nikoubashman, Omid ; Siebert, Eberhard

BACKGROUND::

Vasospasm occurs in up to 20% of patients with acute ischemic stroke undergoing endovascular treatment, but its clinical impact remains controversial. Intraarterial nimodipine is administered occasionally to treat vasospasm, though its efficacy is uncertain. We aimed to identify factors associated with vasospasm, delineate the impact on clinical outcomes, and assess the effects of intraarterial nimodipine use.

METHODS::

We used data from the German Stroke Registry-Endovascular Treatment, an investigator-initiated, prospective, observational, multicenter registry of patients with acute stroke who underwent endovascular treatment at 25 centers between June 2015 and December 2023. Patients with and without vasospasm were analyzed, and among those with vasospasm, we compared outcomes based on intraarterial nimodipine use. The primary outcome was the distribution of modified Rankin Scale scores at 90 days. Secondary outcomes included 90-day mortality, early neurological deterioration, symptomatic intracranial hemorrhage at 24 hours, and successful recanalization (modified Thrombolysis in Cerebral Infarction Score of 2b to 3). Analyses used Inverse Probability of Treatment Weighting adjusted logistic regression; variable selection was performed using Least Absolute Shrinkage and Selection Operator regression.

RESULTS::

Seventeen thousand nine hundred eighty-five patients (mean age 73.6 years; 51.2% female) were included in the analysis. Of these, 578 (3.2%) had vasospasm reported, and 300 (58.4%) of those received intraarterial nimodipine. Vasospasm was associated with a shift towards worse modified Rankin Scale outcome (adjusted odds ratio, 1.25 [95% CI, 1.02–1.53]) and higher mortality (36% versus 29.7%; adjusted odds ratio, 1.35 [95% CI, 1.05–1.75]). Intraarterial nimodipine was associated with reduced rates of early neurological deterioration (adjusted odds ratio, 0.54 [95% CI, 0.31–0.91]). Variables associated with vasospasm included younger age, active smoking, M2 occlusion, first-line stent retriever thrombectomy, and multiple recanalization attempts.

CONCLUSIONS::

Vasospasm during endovascular treatment is associated with worse outcomes and increased mortality, and should be regarded as a serious procedural complication. Younger patients who are active smokers, presenting with distal occlusions, and require multiple recanalization attempts are at higher risk. Intraarterial nimodipine appears to be a sensible treatment as it may mitigate neurological deterioration without signals of potential harm.

01 Feb 2026·JOURNAL OF ALZHEIMERS DISEASE

Reveal the mechanism of action of donepezil combined with nimodipine in the treatment of Alzheimer's disease via metabolomics and lipidomics analyses in rats

Article

Author: Wang, Yibing ; Zhang, Yichun ; Yuan, Zeyang ; Wang, Xinyi ; Liu, Kai ; Ji, Yujie ; Ding, Zhaoqi ; Cui, Xinyuan ; Chang, Zenghui ; Liu, Yuanyuan

Background:

With the aging population, the number of Alzheimer's disease (AD) patients has been increasing annually, creating an urgent need for AD therapeutic drugs. Donepezil combined with nimodipine (DN) has demonstrated therapeutic potential in the treatment of AD, but its mechanism of action remains unclear.

Objective:

To reveal the mechanism of DN in the treatment of AD rats.

Methods:

The AD rat model was established and evaluated by behavioral experiments and pathology. The therapeutic mechanism of DN in AD treatment was investigated through lipidomics and hippocampal metabolomics analyses based on ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UPLC-Q-TOF/MS).

Results:

The learning and memory ability of AD rats can be improved after DN treatment. Significant changes were observed in 40 serum lipid metabolites and 19 hippocampal metabolites. These metabolites are mainly involved in glycerophospholipid metabolism, sphingolipid metabolism, amino acid metabolism, unsaturated fatty acid metabolism and other processes in AD rats.

Conclusions:

DN could improve cognitive function and nerve damage in AD rats. It may plays a therapeutic role in AD rats by regulating cholinergic damage, Ca 2+ overload, oxidative stress, neuroinflammation, and energy deficiency caused by metabolic disorders, which has practical significance for further research and clinical application of DN.

News (Medical) associated with Nimodipine

24 Apr 2026

·www.prnewswire.com

INSIGHTRX INTRODUCES APOLLO STUDIO: A CLINICAL INTELLIGENCE SYSTEM FOR PHARMACY ANALYTICS

SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- InsightRX today announced the launch of Apollo Studio, a new interface within its Apollo platform that enables pharmacy teams to generate clinical analyses and visualizations directly from their own data using natural language. Pharmacy sits on some of the richest clinical data in the hospital, but most of it remains locked in the EHR or buried in informatics workflows. When a pharmacy leader needs to evaluate a protocol, run a medication use evaluation (MUE), analyze pharmacy program performance, or generate clinical analytics for antimicrobial stewardship and other therapeutic areas, the answer is often weeks away. Apollo Studio changes that. This approach builds on deployments across health systems, including Cape Cod Healthcare and CHRISTUS Health, where pharmacy teams used InsightRX to measure and improve clinical program performance. Apollo Studio is designed to replace static pharmacy dashboards, manual data requests, and delayed reporting workflows with real-time clinical intelligence. "Pharmacy already has the data," said Dr. Sirj Goswami, Founder of InsightRX. "The limitation has been the time required to turn that data into something usable. Apollo Studio closes that gap. You describe the clinical objective or reporting requirement, and the system generates the analysis on your own data in real time." From Clinical Questions to Immediate Answers Apollo Studio introduces a natural language analytics and reporting layer that allows users to interact directly with their institutional data. Instead of relying on static dashboards or submitting requests to data teams, clinicians and pharmacy leaders can: Describe the analysis they want in plain language Filter by drug, patient population, time period, and clinical subgroup Instantly generate the corresponding visualization For example, a pharmacy leader conducting a medication use evaluation can identify increased nimodipine utilization and quickly: Review indication, prescribing patterns, and clinical markers such as transcranial Doppler results and Lindegaard ratio Assess performance metrics including target attainment, AUC distributions, and safety outcomes across patient populations Identify variability in prescribing practices and potential use outside of evidence-based indications Intervene in real time with high-utilization providers and validate appropriate use through local outcomes data This reduces the gap between a clinical question and the data required to answer it. A Clinical Intelligence Layer for Pharmacy Performance Apollo Studio operates on top of Apollo, InsightRX's clinical intelligence platform. Apollo provides structured, real-time visibility into: Pharmacokinetic performance Adherence to evidence-based medicine Clinical outcomes and medication effectiveness Clinical competencies CMS quality measures Operational pharmacy metrics Medication use evaluations (resource utilization review) Quality improvement project adoption and success metrics It is designed to give pharmacy teams direct access to actionable data across medication use evaluations, protocol compliance, and outcomes analysis without requiring custom-built reports. Applications such as precision dosing represent one use of this infrastructure. More broadly, Apollo supports how institutions ensure adherence to evidence-based medicine, identify and respond to medication waste and misuse, measure performance, and present outcomes across therapeutic areas. Apollo Studio extends this foundation by enabling real-time analysis and visualization, moving beyond static reporting to on-demand clinical intelligence. About InsightRX InsightRX is a healthcare technology company focused on advancing precision medicine through clinical decision support. Its cloud-based platform combines pharmacokinetic and pharmacodynamic modeling, real-world data, and machine learning to help clinicians individualize therapy at the point of care. The software is used by more than 40,000 clinicians across 1,000+ hospitals, supporting over 5.5 million individualized dosing decisions across critical therapeutic areas, including infectious diseases, bone marrow transplant, anticoagulation, and neurology. InsightRX's platform supports model-informed precision dosing (MIPD), therapeutic drug monitoring, and real-time pharmacy analytics across the enterprise. InsightRX has been recognized as a category leader in model-informed precision dosing, including a KLAS Emerging Company Spotlight with a 96.1 performance score. By connecting pharmacology with real-world evidence, InsightRX enables health systems to measure, understand, and improve treatment performance at scale. Learn more at Media Contact: Nikhil Bilkha, Marketing Director & [email protected] SOURCE InsightRX 21% more press release views with Request a Demo

24 Apr 2026

·endpoints.news

Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug

Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public offering at the midpoint of the range that it is marketing to investors. The biotech is seeking to sell 11.8 million shares $AVLN between $16 and $18 apiece. The Nasdaq float would come shortly after Kailera Therapeutics’ record-breaking IPO last week. — Kyle LaHucik Novartis wins WHO prequalification for newborn malaria drug: The Swiss drugmaker’s Coartem Baby will be added to the WHO’s list of prequalified products, which UN agencies and other public-sector procurers use to guide funding and purchasing decisions. Coartem Baby was approved by the Swiss medicines regulator last year. Novartis is providing the treatment on a largely not-for-profit basis in countries where malaria is endemic. — Ayisha Sharma Grace gets CRL over manufacturing woes: Grace Therapeutics $GRCE has been issued a complete response letter from the FDA for its GTx-104 drug, which is being investigated as a treatment for patients with aneurysmal subarachnoid hemorrhage (aSAH). The drug was rejected over concerns about the asset’s chemistry, manufacturing and controls, including manufacturing deficiencies at Grace’s contract manufacturer. The FDA also found issues in the drug application’s non-clinical data, including toxicology risk assessments. Grace’s stock fell 45% on the news. The company plans to request a Type A meeting with the FDA and expects the issues to be resolved in a resubmission to the agency. — Anna Brown Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.

Drug ApprovalIPO

24 Apr 2026

·allsci.com

Grace Therapeutics receives CRL from US FDA for GTx-104 nimodipine formulation

Grace Therapeutics, Inc. disclosed that the US FDA issued a Complete Response Letter (CRL) for the company’s New Drug Application (NDA) for GTx-104, an intravenous lipid nanoparticle formulation of nimodipine, under review as a treatment for aneurysmal subarachnoid hemorrhage (aSAH). The CRL represents a delay in GTx-104 FDA approval and requires the company to address outstanding items before the agency will consider approving the application. The FDA’s CRL cited deficiencies related to chemistry, manufacturing, and controls (CMC) as well as non-clinical information. The agency did not identify efficacy or clinical safety concerns as the basis for the action. Under the CRL process, Grace Therapeutics must resolve the identified CMC and non-clinical deficiencies and submit a formal resubmission to the FDA before the application can be approved. GTx-104 is a lipid-based nanoparticle formulation of nimodipine, a dihydropyridine L-type voltage-gated calcium channel blocker. Conventional nimodipine is administered orally for the reduction of ischemic deficits following aSAH, a condition in which blood accumulates in the subarachnoid space following rupture of a cerebral aneurysm. Cerebral vasospasm is a leading cause of morbidity and mortality in aSAH patients, and intravenous delivery of nimodipine has historically been limited by the risk of severe systemic hypotension associated with existing IV formulations. GTx-104 was designed to enable IV administration while mitigating that hypotension risk through nanoparticle encapsulation, potentially offering a route of administration more suited to critically ill patients who may not tolerate oral dosing. The application was supported by the Phase III STRIVE-ON trial (NCT05995405), a prospective, randomized, open-label study comparing GTx-104 with oral nimodipine in 102 hospitalized aSAH patients. The trial’s primary endpoint was the incidence of at least one episode of clinically significant hypotension considered reasonably attributable to study drug, as adjudicated by an independent committee. GTx-104 met this endpoint, with 28% of patients in the GTx-104 arm experiencing at least one such episode versus 35% in the oral nimodipine arm — a 19% relative reduction. Secondary measures also favored GTx-104: 54% of patients receiving the IV formulation achieved a relative dose intensity of 95% or higher, compared with 8% on oral nimodipine. Patients on GTx-104 also showed a 29 percentage point higher rate of favorable functional outcomes at 90 days, along with fewer ICU readmissions, ICU days, and ventilator days. Adverse events were comparable between arms, and no deaths were attributed to either study drug. Oral nimodipine, marketed as Nymalize and available in generic form, holds FDA approval for aSAH-related vasospasm prevention. No IV nimodipine formulation currently holds FDA approval in the United States, which represents the clinical differentiation GTx-104 was developed to address. The absence of an approved IV option for this indication defines the unmet need that the Grace Therapeutics drug application sought to fulfill. Grace Therapeutics stated it is working to address the items cited in the CRL and intends to request a Type A meeting with the FDA to discuss the path forward. The company indicated it remains committed to the program, though no revised target action date or resubmission timeline was provided. The CRL’s focus on CMC and non-clinical items, rather than clinical data, may narrow the scope of work required for resubmission, though the complexity of manufacturing deficiencies in nanoparticle formulations can vary. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Clinical ResultNDADrug Approval

100 Deals associated with Nimodipine

External Link

KEGG	Wiki	ATC	Drug Bank
D00438	Nimodipine	C08CA06	DB00393

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nerve injury	China	Bayer Vital GmbH	05 Feb 1993
Intracranial Aneurysm	United States	Bayer Pharmaceuticals Corp.	28 Dec 1988
Subarachnoid Hemorrhage	United States	Bayer Pharmaceuticals Corp.	28 Dec 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aneurysm, Intracranial Berry, 1	Phase 1	Canada	Grace Therapeutics, Inc.	26 Aug 2021
AIDS Dementia Complex	Phase 1	United States	Miles Laboratories, Inc.	31 Aug 2001
Optic Neuropathy, Ischemic	IND Approval	China	Beijing Deli Furui Pharmaceutical Technology Co. Ltd.	12 Nov 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2023	Not Applicable	Retinal Artery Occlusion	-	Selective intra-ophthalmic arterial combined nimodipine and alteplase	bphcdeflfw(awzqxojtao) = There were also asymptomatic thromboembolic events in 2 patients (22.2%) after interventional procedure without any morbidity or mortality gehjfgmpjo (jglpitmrav ) View more	-	05 Oct 2023
NCT02893826 (NEWTON-2, Pubmed \| Neurosurgery) Manual	Phase 2	Subarachnoid Hemorrhage \| Aneurysm, Intracranial Berry, 1	6	EG-1962	swachhqnsz(zywyfcqdgy) = ogpnxixdxl imyfbkbudj (nmlgrjaznu ) View more	Negative	15 Dec 2020
				nimodipine	swachhqnsz(zywyfcqdgy) = qpyrppupix imyfbkbudj (nmlgrjaznu ) View more
NCT01672801 (NIMO, CTgov)	Not Applicable	Polycystic Ovary Syndrome \| Infertility \| Anovulation	18	Placebo (Placebo)	wwapgvjiew = ysxdladgcu tymbggwvae (rkgnunevsq, hpdwtnpltj - bxseqzzahl) View more	-	11 Aug 2020
				Nimodipine (Nimodipine)	wwapgvjiew = ymvojgkltf tymbggwvae (rkgnunevsq, ipvvvdnqqm - wwuhnezmsc) View more
NCT02790632 (Pubmed \| Stroke)	Phase 1/2	Aneurysm, Intracranial Berry, 1	289	EG-1962	uufydlgvew(loeamgmjyw) = hozywtzxyv ucyvmshngg (dgwoikyrog ) View more	Negative	01 Apr 2020
				Placebo	uufydlgvew(loeamgmjyw) = rnesnlgkpl ucyvmshngg (dgwoikyrog ) View more
WCN2019	Not Applicable	Cerebral Intraventricular Hemorrhage	20	nimodipine (Surgical treatment for VP shunt)	wkvxghqfkk(dahkoyzkhm) = lwqbnvojpu wzwyfwvzbe (mklaitkcvj ) View more	-	15 Oct 2019
				Non-surgical therapy with nimodipine	uzxssnghac(xnvwwpmmsa) = qzaopemnys gyjodtkqwi (wesyylqdbg ) View more
NCT01220622 (Pubmed \| Sci Bull (Beijing))	Phase 4	Acute Ischemic Stroke	654	Nimodipine 30mg	goqwemvmdb(tlfcnjxmxy): Odds Ratio = 1.79 (95% CI, 1.18 - 2.7)	-	30 Jan 2019
				Placebo
NCT01893190 (NEWTON, Pubmed \| Cochrane Database Syst Rev \| Stroke) Manual	Phase 1/2	Subarachnoid Hemorrhage	72	EG-1962	xmsytzqouy(nxqmwlplkt) = rvaxthljpf ovgkjdctez (guecytujgh ) View more	Positive	01 Jan 2017
				nimodipine	rktivphdmh(rcyvtbxmyj) = oflebavqqf atruiokxpz (igtiqeuhcc, 7 - 48) View more
NCT00781326 (CTgov)	Phase 4	-	9	Placebo+Nimodipine	kjvnunweqf(igxpuirqtd) = hshvxhwqko gonwikkdtl (ifbpvvezxx, 0.7) View more	-	29 Sep 2016
NCT01893190 (ISC2016)	Phase 1/2	Subarachnoid Hemorrhage	45	EG-1962	vkkkdfmnrg(lgmwhhzdoi) = two EG-1962 dose limiting toxicities (increased intracranial pressure, 400 and 800 mg) ylcbqtjsss (brkximtjkq ) View more	Positive	01 Feb 2016
				Oral nimodipine

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis